



reductive ring opening reaction of isoxazolines by Nonn, Melinda et al.
100
Synthesis of highly functionalized
β-aminocyclopentanecarboxylate stereoisomers by
reductive ring opening reaction of isoxazolines
Melinda Nonn1, Loránd Kiss1, Reijo Sillanpää2 and Ferenc Fülöp*1,3
Full Research Paper Open Access
Address:
1Institute of Pharmaceutical Chemistry, University of Szeged, Eötvös
u. 6, H-6720 Szeged, Hungary, 2Department of Chemistry, University
of Jyväskylä, FIN-40014 Jyväskylä, Finland and 3Stereochemistry
Research Group of the Hungarian Academy of Sciences, University of
Szeged, Eötvös u. 6, H-6720 Szeged, Hungary
Email:
Ferenc Fülöp* - fulop@pharm.u-szeged.hu
* Corresponding author
Keywords:
amino acids; cycloaddition; functionalization; isoxazolines; reduction
Beilstein J. Org. Chem. 2012, 8, 100–106.
doi:10.3762/bjoc.8.10
Received: 05 October 2011
Accepted: 23 December 2011
Published: 17 January 2012
Associate Editor: D. Dixon
© 2012 Nonn et al; licensee Beilstein-Institut.
License and terms: see end of document.
Abstract
A rapid and simple procedure was devised for the synthesis of multifunctionalized cyclic β-amino esters and γ-amino alcohols via
the 1,3-dipolar cycloaddition of nitrile oxides to β-aminocyclopentenecarboxylates. The opening of the isoxazoline reductive ring to
the corresponding highly functionalized 2-aminocyclopentanecarboxylates occurred stereoselectively with good yields.
Introduction
Isoxazoline-fused amino acids are important bioactive deriva-
tives in organic and medicinal chemistry (e.g., conformation-
ally restricted aspartate and glutamate analogues) [1-6]. As a
consequence of their ability to undergo reductive ring opening,
isoxazolines are of interest as precursors for the synthesis of
highly functionalized molecules such as β-hydroxyketones
[7-10], amino alcohols or amino acids [11-17], etc. The multi-
functionalized cyclic amino acids – e.g., the antibiotic
Oryzoxymycin [18-21], the antiviral agents Tamiflu [22-33],
Zanamivir and 2,3-didehydro-2-deoxy-N-acetylneuraminic acid
(DANA) [34-38] – are bioactive derivatives of great signifi-
cance for medicinal chemistry. A promising neuraminidase
inhibitor, BCX-1812 (Peramivir), is currently under evaluation
in clinical trials [39-45] (Figure 1). A series of Peramivir
analogues has recently been investigated as potential antiviral
agents [46,47].
Results and Discussion
We recently reported a regio- and stereoselective procedure for
the formation of a series of isoxazoline-fused cispentacin and
transpentacin regio- and stereoisomers (2–6) from bicyclic
β-lactam 1 [48,49] (Scheme 1). The syntheses consisted of a
dipolar cycloaddition of nitrile oxide (generated with Boc2O,
Et3N and DMAP) to the olefinic bond of cis-ethyl 2-amino-
cyclopent-3-enecarboxylate derived from 1, during which the
isoxazoline-fused amino ester regio- and stereoisomers (2 and
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Figure 1: Structures of neuraminidase inhibitors.
Scheme 1: Isoxazoline-fused β-aminocyclopentanecarboxylate regio- and stereoisomers [8].
4) were formed, then separated and isolated. The cycloaddition
of nitrile oxide to trans-ethyl 2-aminocyclopent-3-enecarboxy-
late under similar conditions proceeded selectively with the for-
mation of 6. Epimerization of 2 and 4 afforded trans deriva-
tives 3 and 5 [48,49].
Since isoxazoline-functionalized molecules are excellent
precursors for the construction of different functional groups
through reductive ring cleavage, our recent aim was to synthe-
size highly functionalized β-aminocyclopentanecarboxylate
regio- and stereoisomers from the earlier prepared isoxazoline-
fused cispentacin and transpentacin derivatives.
A number of methods are known for the reductive opening of
the isoxazoline ring: Catalytic hydrogenation or reduction with
Fe in the presence of NH4Cl, NaBH4, LiAlH4, Raney Ni,
BH3·THF, or SmI2/B(OH)3/H2O [7-17].
For the reduction, we selected model compound 2 from earlier
prepared isoxazoline-fused cispentacin stereoisomers to execute
the reduction under different conditions. The isoxazoline-fused
derivative was treated with the above-mentioned reducing
agents. Unfortunately, neither transformation nor isoxazoline
opening with ester reduction was observed. When the reduction
was carried out with NaBH4 in EtOH, three products were
obtained: The epimerized isoxazoline-fused amino carboxylate
7 and amino alcohols 8 and 9 which were separated by chroma-
tography and isolated (Scheme 2).
Thus, this reaction did not lead to the formation of highly func-
tionalized isoxazoline ring-opened β-amino ester either. When
ammonium formate in EtOH in the presence of Pd/C was
investigated for the reduction of 2, the ring opening resulted in
carbonyl compound 10 in rather low yield through the corres-
ponding hydroxyimine intermediate, followed by elimination
and saturation (Scheme 3).
Combinations of NaBH4 (as a mild and selective reducing
agent) with cobalt, nickel, iridium or rhodium halide have
previously been employed for cleavage of the isoxazoline ring
system, which is otherwise inert to NaBH4 without such metal
halide additives [50]. Accordingly, we investigated the reduc-
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Scheme 2: Treatment of isoxazoline-fused amino ester 2 with NaBH4.
Scheme 4: Transformation of isoxazoline-fused cispentacin stereoisomer 2 into multifunctionalized β-amino acid derivative 12.
Scheme 3: Reduction with Pd/C in the presence of HCO2NH4.
tion of isoxazoline-fused amino ester stereoisomers 2 [48,49]
with NaBH4 in the presence of NiCl2 (Scheme 4), which was
found to be a suitable reducing system.
The reduction carried out by adding NaBH4 to a mixture of
NiCl2 and isoxazoline derivative 2 in EtOH/H2O, followed by
amino group protection with Boc2O, selectively afforded only
isoxazoline-opened product 12 as a single diastereomer in good
yield. The reaction was exothermic and deposited a black gran-
ular precipitate, reflecting the presence of metal boride. The
product was purified by column chromatography and the struc-
ture of 12 was certified by X-ray analysis (Figure 2).
The isoxazoline opening occurred with the formation of a new
stereocenter at a one-carbon distance from C-3. In accordance
with earlier results [39-47], the hydrogenation of the isoxazo-
line proceeded through hydrogen attack from the carbamate side
(cis to –NHBoc) of the cyclopentane skeleton. This was
confirmed by X-ray analysis of 12.
In order to increase the number of multifunctionalized amino
ester stereoisomers, we next examined the reductions of isoxa-
zoline-fused cispentacin and transpentacin stereoisomers (3–6)
Figure 2: ORTEP diagram of 12 showing the atomic labeling scheme.
The thermal ellipsoids are drawn at the 20% probability level.
[49]. Reactions were carried out similarly with NaBH4 in the
presence of NiCl2 in EtOH/H2O and led selectively to the
corresponding multifunctionalized amino esters 13–16 in good
yields (Scheme 5) as single diastereoisomers.
Conclusion
The present work has furnished a facile and efficient stereose-
lective reduction of isoxazoline-fused cyclic β-amino esters to
multifunctionalized 2-aminocyclopentanecarboxylates through
the use of NaBH4/NiCl2 as reducing agent. As Peramivir related
derivatives, highly functionalized cyclic amino esters may be
regarded as promising bioactive compounds.
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Scheme 5: Synthesis of multifunctionalized β-amino acid derivatives
13–16. Reaction conditions: NaBH4, NiCl2, Boc2O, EtOH/H2O, rt, 6 h.
Experimental
The chemicals were purchased from Aldrich. The solvents were
used as received from the supplier. Melting points were deter-
mined with a Kofler apparatus. NMR spectra were recorded on
a Bruker DRX 400 MHz spectrometer in deuterated DMSO or
CDCl3. Chemical shifts are expressed in ppm (δ) from the
signal of internal tetramethylsilane. Mass spectra were recorded
on a Finnigan MAT 95S spectrometer. Elemental analyses were
recorded on a Perkin-Elmer CHNS-2400 Ser II Elemental
Analyzer. FTIR spectra were recorded on a Perkin-Elmer Spec-
trum 100 instrument. Cycloadducts 2–6 were synthesized
according to previously published procedures [8].
General procedure for the synthesis of com-
pounds 8 and 9
To a solution of izoxazoline-fused β-aminocyclopentane-
carboxylate 2 (0.96 mmol) in dry EtOH (15 mL) NaBH4
(2.88 mmol) was added and the reaction mixture was stirred
under reflux for 16 h. The reaction was quenched by the addi-
tion of H2O (10 mL) and then, the mixture was concentrated
under reduced pressure. The reaction mixture was diluted with
H2O (20 mL), washed with EtOAc (3 × 15 mL), dried
(Na2SO4) and concentrated under reduced pressure. The crude
residue was purified by column chromatography on silica gel
(n-hexane/EtOAc) giving 8 and 9.
General procedure for the synthesis of 10
To a stirred solution of isoxazoline-fused β-aminocyclopentane-
carboxylate 2 (1.6 mmol) in dry EtOH (15 mL), HCOONH4
(3.2 mmol) and Pd/C (0.10 g) were added and the reaction mix-
ture was stirred under reflux for 24 h. The mixture was filtered
through a celite pad and the filtrate was evaporated in vacuo.
The crude residue was diluted with EtOAc (30 mL), washed
with H2O (3 × 15 mL), dried over Na2SO4 and concentrated
under reduced pressure. The residue was purified by column
chromatography on silica gel (n-hexane/EtOAc), giving 10.
General procedure for isoxazoline ring
opening
To a stirred solution of isoxazoline-fused β-aminocyclopentane-
carboxylates 2–6 (0.96 mmol) in 8 mL of EtOH/THF (v:v =
3:1), NiCl2 (1.92 mmol) and Boc2O (1.92 mmol) were added.
After stirring for 10 min, NaBH4 (1.92 mmol) was added in
portions. The reaction mixture was further stirred for 6 h at
room temperature and the reaction was quenched by the addi-
tion of H2O (5 mL). The reaction mixture was filtered through a
celite pad and the filtrate was evaporated in vacuo. The crude
residue was diluted with EtOAc (30 mL), washed with H2O
(3 × 15 mL), dried over Na2SO4, and concentrated under
reduced pressure. The residue was purified by column chroma-




yl]carbamate (8): Light-yellow oil; yield 48% (124 mg); Rf
0.35 (n-hexane/EtOAc); IR (KBr) ν/cm–1: 3344, 3265, 2979,
1678, 1563, 1184; 1H NMR (400 MHz, CDCl3) δ 1.45 (s, 3H,
CH3), 1.56 (s, 9H, CH3), 1.65–1.72 (m, 2H, CH2), 2.19–2.25
(m, 1H, H-5), 2.75–2.81 (m, 1H, H-3a), 3.19–3.25 (m, 1H,
H-6a), 3.59–3.71 (m, 1H, H-4), 3.63–3.72 (m, 2H, CH2), 5.42
(br s, 1H, N-H), OH group not observed – exchanged;
13C NMR (100 MHz, CDCl3) δ 16.0, 28.6, 30.2, 32.5, 43.0,
44.4, 59.2, 63.9, 78.0, 155.2, 155.6; MS (ESI) m/z: 293 [M +
Na]+; Anal. calcd for C13H22N2O4: C, 57.76; H, 8.20; N, 10.36;
found: C, 57.60; H, 8.07; N, 10.23.
tert-Butyl (3S*,3aR*,4R*,5R*,6aR*)-[5-(hydroxymethyl)-3-
methylhexahydro-2H-cyclopenta[d]isoxazol-4-yl]carbamate
(9): Colorless oil; yield 12% (31 mg); Rf 0.29 (n-hexane/
EtOAc); IR (KBr) ν/cm–1: 3460, 3331, 2978, 1683, 1531, 1174;
1H NMR (400 MHz, CDCl3) δ 0.98–1.05 (m, 3H, CH3), 1.36 (s,
9H, CH3), 1.55–1.75 (m, 2H, CH2), 2.22–2.27 (m, 1H, H-5),
2.38–2.47 (m, 1H, H-3a), 2.78–2.86 (m, 1H, H-3), 3.17–3.24
(m, 1H, H-6a), 3.59–3.69 (m, 1H, H-4), 3.36–3.68 (m, 2H,
CH2), 5.32 (br s, 1H, N-H), 6.12 (br s, 1H, N-H), OH group not
observed – exchanged; 13C NMR (100 MHz, CDCl3) δ 15.0,
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27.1, 29.0, 35.8, 42.4, 51.7, 57.2, 62.6, 77.4, 80.4, 155.6; MS
(ESI) m/z: 295 [M + Na]+; Anal. calcd for C13H24N2O4: C,
57.33; H, 8.88; N, 10.29; found: C, 57.20; H, 8.71; N, 10.42.
Ethyl (1R*,2S*,3S*)-3-acetyl-2-(tert-butoxycarbonyl-
amino)cyclopentanecarboxylate (10): White solid; yield 32%
(153 mg); mp 109–110 °C; Rf 0.62 (n-hexane/EtOAc); IR (KBr)
ν/cm–1: 3354, 2978, 1716, 1684, 1531, 1171; 1H NMR (400
MHz, CDCl3) δ 1.29 (t, J = 7.54 Hz, 3H, CH3), 1.41 (s, 9H,
CH3), 1.59–1.71 (m, 2H, CH2), 1.74–1.95 (m, 2H, CH2), 2.05
(s, 3H, CH3), 2.83–2.97 (m, 1H, H-1), 3.01–3.15 (m, 1H, H-3),
4.18–4.29 (m, 2H, OCH2), 4.31–4.44 (m, 1H, H-2), 5.76 (br s,
1H, N-H); 13C NMR (100 MHz, CDCl3) δ 13.98, 20.05, 25.76,
29.31, 31.21, 43.97, 46.01, 52.70, 82.01, 155.67, 176.01,
206.52; MS (ESI) m/z: 322 [M + Na]+; Anal. calcd for




late (12): White solid; yield 80% (320 mg); mp 120–121 °C; Rf
0.22 (n-hexane/EtOAc 1:1); IR (KBr) ν/cm–1: 3457, 3348,
2982, 1720, 1698, 1531, 1160; 1H NMR (400 MHz, DMSO) δ
0.96 (t, J = 7.34 Hz, 3H, CH3), 1.27–1.33 (m, 3H, CH3),
1.45–1.50 (m, 18H, CH3), 1.94–2.02 (m, 2H, CH2), 2.07–2.16
(m, 1H, H-4), 3.30–3.39 (m, 1H, H-1), 3.80–3.89 (m, 1H, CH),
4.13–4.23 (m, 2H, OCH2), 4.24–4.30 (m, 1H, H-2), 4.44–4.56
(m, 1H, H-3), 5.28–5.35 (m, 1H, NH), 5.61–5.72 (m, 1H, NH),
OH group not observed – exchanged; 13C NMR (100 MHz,
CDCl3) δ 11.7, 14.6, 28.8, 28.9, 29.3, 30.1, 31.8, 37.3, 44.6,
51.1, 54.6, 61.2, 73.7, 80.1, 80.4, 155.0, 156.5, 172.0; MS (ESI)
m/z: 418 [M + 2H]+; Anal. calcd for C20H36N2O7: C, 57.67; H,
8.71; N, 6.73; found: C, 57,44; H, 8.86; N, 6.58.
Ethyl (1R*,2R*,3R*,4S*)-2-(tert-butoxycarbonyl)-4-((R*)-1-
(tert-butoxycarbonyl)ethyl)-3-hydroxycyclopentanecarboxy-
late (13): White solid; yield 72% (288 mg); mp 129–130 °C; Rf
0.59 (n-hexane/EtOAc 1:1); IR (KBr) ν/cm–1: 3479, 3347,
3353, 1725, 1685, 1662, 1531, 1163; 1H NMR (400 MHz,
CDCl3) δ 1.17–1.29 (m, 6H, CH3), 1.40–1.46 (m, 18H, CH3),
1.79–1.91 (m, 1H, CH2), 2.05–2.19 (m, 2H, CH2, H-1),
3.26–3.34 (m, 1H, H-4), 3.86–4.01 (m, 2H, H-2, CH),
4.08–4.19 (m, 3H, OCH2, H-3), 4.53 (br s, 1H, N-H), 5.05 (br s,
1H, N-H), OH group not observed – exchanged; 13C NMR (100
MHz, CDCl3) δ 14.6, 21.1, 28.4, 28.7, 28.8, 44.0, 46.6, 60.5,
61.2, 67.5, 77.6, 80.2, 86.4, 156.1, 156.4, 174.8; MS (ESI) m/z:
418 [M + 2H]+; Anal. calcd for C20H36N2O7: C, 57.67; H, 8.71;
N, 6.73; found: C, 57.50; H, 8.98; N, 6.39.
Ethyl (1S*,2S*,3S*,4R*)-2-(tert-butoxycarbonyl)-3-((S*)-1-
(tert-butoxycarbonyl)ethyl)-4-hydroxycyclopentanecarboxy-
late (14): White solid; yield 75% (300 mg); mp 144–145 °C; Rf
0.3 (n-hexane/EtOAc 1:1); IR (KBr) ν/cm–1: 3420, 3363, 2980,
1692, 1537, 1185; 1H NMR (400 MHz, CDCl3) δ 1.26–1.33 (m,
6H, CH3), 1.43–1.48 (m, 18H, CH3), 1.82–1.93 (m, 1H, CH2),
1.98–2.15 (m, 1H, H-1), 2.24–2.36 (m, 1H, CH2), 2.76–2.89
(m, 1H, H-3), 3.58–3.72 (m, 1H, H-4), 3.93–4.05 (m, 1H, H-2),
4.15–4.25 (m, 3H, OCH2, CH), 4.87 (br s, 1H, N-H), 5.09 (br s,
1H, N-H), OH group not observed – exchanged; 13C NMR (100
MHz, CDCl3) δ 14.5, 21.4, 28.8, 28.9, 35.9, 45.7, 49.1, 52.3,
54.5, 58.3, 73.4, 80.1, 152.5, 156.8, 172.6; MS (ESI) m/z: 418
[M + 2H]+; Anal. calcd for C20H36N2O7: C, 57.67; H, 8.71; N,
6.73; found: C, 57.41; H, 8.37; N, 6.59.
Ethyl (1S*,2R*,3R*,4S*)-2-(tert-butoxycarbonyl)-4-((R*)-1-
(tert-butoxycarbonyl)ethyl)-3-hydroxycyclopentanecarboxy-
late (15): White solid; yield 85% (340 mg); mp 141–142 °C; Rf
0.46 (n-hexane/EtOAc 1:1); IR (KBr) ν/cm–1: 3426, 3378,
3333, 2979, 1688, 1718, 1703, 1522, 1176; 1H NMR (400
MHz, CDCl3) δ 1.21–1.30 (m, 6H, CH3), 1.40–1.46 (m, 18H,
CH3), 1.84–1.97 (m, 2H, CH2, H-4), 2.03–2.20 (m, 2H, CH2,
H-1), 2.54 (q, J = 9.10 Hz, 1H, H-2,), 3.73–3.82 (m, 1H, H-3),
3.87–4.04 (m, 2H, N-H, CH), 4.10–4.22 (m, 2H, OCH2), 4.83
(br s, 1H, N-H), OH group not observed – exchanged;
13C NMR (100 MHz, CDCl3) δ 14.1, 20.0, 27.5, 28.7, 28.8,
45.6, 46.1, 46.8, 60.9, 62.5, 78.1, 80.1, 80.3, 154.0, 156.4,
174.6; MS (ESI) m/z: 418 [M + 2H]+; Anal. calcd for




late (16): White solid; yield 82% (328 mg); mp 166–167 °C; Rf
0.32 (n-hexane/EtOAc 1:1); IR (KBr) ν/cm–1: 3485, 3368,
3353, 2975, 1733, 1681, 1667, 1533, 1167; 1H NMR (400
MHz, CDCl3) δ 1.17–1.31 (m, 6H, CH3), 1.38–1.46 (m, 18H,
CH3), 1.79–2.15 (m, 3H, CH2, H-1, H-4), 2.72–2.87 (m, 1H,
CH2), 3.77–4.03 (m, 1H, CH), 4.06–4.23 (m, 4H, H-2, H-3,
OCH2), 4.37–4.48 (m, 1H, N-H), 4.88 (br s, 1H, N-H), OH
group not observed – exchanged; 13C NMR (100 MHz, CDCl3)
14.6, 21.6, 28.7, 28.8, 47.2, 49.0, 59.9, 61.2, 61.6, 69.4, 74.7,
80.0, 85.9, 117.5, 156.1, 158.8, 171.3; MS (ESI) m/z: 418 [M +
2H]+; Anal. calcd for C20H36N2O7: C, 57.67; H, 8.71; N, 6.73;
found: C, 57.43; H, 8.40; N, 6.95.
X-ray crystallographic study of 12: Crystallographic data
were collected at 123 K with a Nonius-Kappa CCD area
detector diffractometer, using graphite-monochromatized
Mo Ka radiation (λ = 0.71073 Å) as reported earlier [51].
Crystal data for 12, C20H36N2O7, Mr = 416.51, triclinic, space
group P−1 (no. 2), a = 9.3765(2), b = 13.7078(4), c =
18.7792(4) Å, α = 96.609(2), β = 95.261(1), γ = 100.965(1), V =
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2337.9(1) Å3, T = 123 K, Z = 4, μ(Mo Kα) = 0.089 mm–1, 9120
unique reflections (Rint = 0.034) which were used in calcula-
tions. The final R1 (for the data with F2 > 2δ(F2) was 0.042 and
wR2(F2) (all data) was 0.111.
The SHELXL-97 program [52] was used to solve the structure
by direct methods and to perform full-matrix, least-squares
refinements on F2. The unit cell of 12 contains two molecules
with slightly different conformations. The CH hydrogen atoms
were included at fixed distances from their host atoms with
fixed displacement parameters. The NH and OH hydrogen
atoms were refined isotropically. The deposition number CCDC
845835 contains the supplementary crystallographic data for
this paper. These data can be obtained free of charge at http://
www.ccdc.cam.ac.uk/conts/retrieving.html [or from the
Cambridge Crystallographic Data Centre, 12 Union Road,
Cambridge CB2 1EZ, UK; Fax: (internat.) +44-1223-336-033;
Email: deposit@ccdc.cam.ac.uk].
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